EP 4380982 A1 20240612 - PROSTATE CANCER TREATMENT OR TREATMENT OF GYNECOLOGIC OR GENITOURINARY MALIGNANCY WITH A BISPECIFIC ANTIBODY THAT BINDS CTLA4 AND PD1
Title (en)
PROSTATE CANCER TREATMENT OR TREATMENT OF GYNECOLOGIC OR GENITOURINARY MALIGNANCY WITH A BISPECIFIC ANTIBODY THAT BINDS CTLA4 AND PD1
Title (de)
PROSTATAKREBSBEHANDLUNG ODER BEHANDLUNG GYNÄKOLOGISCHER ODER UROGENITALER MALIGNITÄT MIT EINEM BISPEZIFISCHEN ANTIKÖRPER ZUR BINDUNG VON CTLA4 UND PD1
Title (fr)
TRAITEMENT DU CANCER DE LA PROSTATE OU TRAITEMENT DE LA MALIGNITÉ GYNÉCOLOGIQUE OU GÉNITO-URINAIRE AVEC UN ANTICORPS BISPÉCIFIQUE QUI SE LIE À CTLA4 ET PD1
Publication
Application
Priority
- US 202163230531 P 20210806
- US 202163230583 P 20210806
- US 202163230605 P 20210806
- US 202163238616 P 20210830
- US 202263346194 P 20220526
- US 2022074603 W 20220805
Abstract (en)
[origin: WO2023015292A1] Provided herein, in certain aspects, are methods of treating a cancer in a subject, comprising administering a bispecific anti-CTLA4 x anti-PD1 antibody to the subject.
IPC 8 full level
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01)
CPC (source: EP US)
A61K 31/337 (2013.01 - EP); A61K 31/555 (2013.01 - EP); A61K 31/573 (2013.01 - EP); A61P 35/00 (2018.01 - EP US); C07K 16/2818 (2013.01 - EP); C07K 16/2827 (2013.01 - EP US); C07K 16/2896 (2013.01 - EP US); C07K 16/3069 (2013.01 - EP); C07K 16/468 (2013.01 - EP); A61K 2039/505 (2013.01 - EP US); A61K 2039/545 (2013.01 - US); C07K 2317/24 (2013.01 - US); C07K 2317/31 (2013.01 - EP US); C07K 2317/55 (2013.01 - EP US); C07K 2317/622 (2013.01 - US)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2023015292 A1 20230209; EP 4380982 A1 20240612; US 2023074793 A1 20230309
DOCDB simple family (application)
US 2022074603 W 20220805; EP 22782792 A 20220805; US 202217817845 A 20220805